AUD2.83
10.98% day before yesterday
Australia, Dec 27, 06:10 am CET
ISIN
AU000000MSB8
Symbol
MSB
Sector
Industry

Mesoblast Stock price

AUD2.83
+1.07 60.80% 1M
+1.85 188.78% 6M
+2.52 812.90% YTD
+2.54 875.86% 1Y
+1.51 114.74% 3Y
+0.84 42.13% 5Y
-1.32 31.79% 10Y
Australia, Closing price Fri, Dec 27 2024
+0.28 10.98%
ISIN
AU000000MSB8
Symbol
MSB
Sector
Industry

Key metrics

Market capitalization AUD3.24b
Enterprise Value AUD3.33b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 369.34
P/S ratio (TTM) P/S ratio 360.04
P/B ratio (TTM) P/B ratio 4.49
Revenue growth (TTM) Revenue growth -18.29%
Revenue (TTM) Revenue AUD9.01m
EBIT (operating result TTM) EBIT AUD-89.75m
Free Cash Flow (TTM) Free Cash Flow AUD-85.09m
Cash position AUD107.14m
EPS (TTM) EPS AUD-0.14
P/E forward negative
P/S forward 174.53
EV/Sales forward 179.04
Show more

Is Mesoblast a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Mesoblast Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Mesoblast forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Mesoblast forecast:

Buy
67%
Hold
33%

Financial data from Mesoblast

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
9.01 9.01
22% 22%
100%
- Direct Costs 24 24
42% 42%
266%
-15 -15
47% 47%
-166%
- Selling and Administrative Expenses 29 29
23% 23%
321%
- Research and Development Expense 39 39
4% 4%
429%
-83 -83
-
-917%
- Depreciation and Amortization 7.12 7.12
-
79%
EBIT (Operating Income) EBIT -90 -90
17% 17%
-996%
Net Profit -134 -134
10% 10%
-1,488%

In millions AUD.

Don't miss a Thing! We will send you all news about Mesoblast directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today